Atria Investments Inc Purchases 35,806 Shares of Kenvue Inc. $KVUE

Atria Investments Inc grew its position in shares of Kenvue Inc. (NYSE:KVUE) by 24.3% in the second quarter, HoldingsChannel reports. The fund owned 183,176 shares of the company’s stock after acquiring an additional 35,806 shares during the period. Atria Investments Inc’s holdings in Kenvue were worth $3,834,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in KVUE. Allspring Global Investments Holdings LLC increased its stake in Kenvue by 1.7% in the 1st quarter. Allspring Global Investments Holdings LLC now owns 87,136 shares of the company’s stock valued at $2,081,000 after buying an additional 1,477 shares during the last quarter. Vontobel Holding Ltd. grew its holdings in shares of Kenvue by 46.0% in the 1st quarter. Vontobel Holding Ltd. now owns 45,744 shares of the company’s stock valued at $1,097,000 after acquiring an additional 14,409 shares in the last quarter. Rossby Financial LCC bought a new stake in Kenvue during the first quarter worth about $52,000. Mutual Advisors LLC increased its position in shares of Kenvue by 5.7% during the 1st quarter. Mutual Advisors LLC now owns 15,994 shares of the company’s stock worth $368,000 after purchasing an additional 867 shares during the last quarter. Finally, OneDigital Investment Advisors LLC increased its holdings in Kenvue by 13.2% during the first quarter. OneDigital Investment Advisors LLC now owns 21,790 shares of the company’s stock worth $523,000 after buying an additional 2,538 shares during the last quarter. Institutional investors own 97.64% of the company’s stock.

Kenvue Price Performance

Kenvue stock opened at $14.40 on Monday. The company has a market capitalization of $27.63 billion, a price-to-earnings ratio of 19.45, a PEG ratio of 2.07 and a beta of 0.72. The company has a current ratio of 0.98, a quick ratio of 0.68 and a debt-to-equity ratio of 0.66. Kenvue Inc. has a 12 month low of $14.02 and a 12 month high of $25.17. The stock’s 50 day moving average is $17.21 and its 200-day moving average is $20.50.

Kenvue (NYSE:KVUE) last released its quarterly earnings results on Thursday, August 7th. The company reported $0.29 earnings per share for the quarter, topping the consensus estimate of $0.28 by $0.01. Kenvue had a return on equity of 20.06% and a net margin of 9.37%.The business had revenue of $3.84 billion during the quarter, compared to analysts’ expectations of $3.94 billion. During the same period last year, the firm posted $0.32 EPS. The firm’s revenue for the quarter was down 4.0% compared to the same quarter last year. Kenvue has set its FY 2025 guidance at 1.000-1.050 EPS. Equities research analysts expect that Kenvue Inc. will post 1.14 EPS for the current year.

Kenvue Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, November 26th. Investors of record on Wednesday, November 12th will be paid a $0.2075 dividend. The ex-dividend date is Wednesday, November 12th. This represents a $0.83 annualized dividend and a dividend yield of 5.8%. Kenvue’s dividend payout ratio is 112.16%.

Analyst Upgrades and Downgrades

KVUE has been the subject of a number of recent analyst reports. Bank of America cut their price target on shares of Kenvue from $25.00 to $21.00 and set a “buy” rating for the company in a research note on Wednesday, October 8th. The Goldman Sachs Group cut their target price on shares of Kenvue from $22.00 to $19.00 and set a “neutral” rating for the company in a research note on Thursday, October 2nd. UBS Group lowered their price target on Kenvue from $23.00 to $17.00 and set a “neutral” rating on the stock in a research report on Wednesday, October 8th. Evercore ISI set a $18.00 price objective on Kenvue in a research report on Tuesday, October 28th. Finally, Zacks Research upgraded Kenvue to a “strong sell” rating in a research note on Monday, August 11th. One investment analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, eleven have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $20.17.

Kenvue Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.